Evidence map›Paper›PMID 27245663›Full record

ArticleActa neuropathologica communications2016

Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study.

Donato Iacovazzo, Richard Caswell, Benjamin Bunce, Sian Jose, Bo Yuan, Laura C Hernández-Ramírez, Sonal Kapur, Francisca Caimari, Jane Evanson, Francesco Ferraù and 25 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00461188 (Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA), which is not on this map. Cited by 50 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 3 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00461188 recruitingnot on this map

Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA

TypeobservationalSponsorBarts & The London NHS TrustRan2007 to 2037Enrolled10,000ConditionsAcromegaly, Gigantism, Familial Isolated Pituitary Adenoma, FIPA
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 134 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Irish giants: from myth to medicine.Irish journal of medical science · 2026
    Article
  5. Review
  6. Article
  7. Genetics of familial acromegaly and pituitary gigantism.The Journal of clinical endocrinology and metabolism · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Fibrous bodies in pituitary adenoma.Medical journal, Armed Forces India · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Pituitary Tumorigenesis-Implications for Management.Medicina (Kaunas, Lithuania) · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 20 institutions in 9 countries.

Donato IacovazzoCentre for Endocrinology, Barts and The London School of Medicine, London, EC1M 6BQ, UK.
Richard CaswellInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, EX2 5DW, UK.
Benjamin BunceInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, EX2 5DW, UK.
Sian JoseInstitute of Medical Genetics, Cardiff University, Cardiff, CF14 4XN, UK.
Bo YuanDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
Laura C Hernández-RamírezCentre for Endocrinology, Barts and The London School of Medicine, London, EC1M 6BQ, UK.
Sonal KapurCentre for Endocrinology, Barts and The London School of Medicine, London, EC1M 6BQ, UK.
Francisca CaimariCentre for Endocrinology, Barts and The London School of Medicine, London, EC1M 6BQ, UK.
Jane EvansonDepartment of Radiology, Barts Health NHS Trust, London, EC1A 7BE, UK.
Francesco FerraùCentre for Endocrinology, Barts and The London School of Medicine, London, EC1M 6BQ, UK.
Mary N DangCentre for Endocrinology, Barts and The London School of Medicine, London, EC1M 6BQ, UK.
Plamena GabrovskaCentre for Endocrinology, Barts and The London School of Medicine, London, EC1M 6BQ, UK.
Sarah J LarkinDepartment of Neuropathology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX1 2JD, UK.
Olaf AnsorgeDepartment of Neuropathology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX1 2JD, UK.
Celia RoddDepartment of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, R3T 2 N2, Canada.
Mary L VanceDepartment of Endocrinology, University of Virginia, Charlottesville, 22908, USA.
Claudia Ramírez-RenteriaEndocrinology Service and Experimental Endocrinology Unit, Hospital de Especialidades Centro Médico Nacional Siglo XXI, IMSS, UNAM, Mexico City, 06720, Mexico.
Moisés MercadoEndocrinology Service and Experimental Endocrinology Unit, Hospital de Especialidades Centro Médico Nacional Siglo XXI, IMSS, UNAM, Mexico City, 06720, Mexico.
Anthony P GoldstoneImperial Centre for Endocrinology, Imperial College Healthcare NHS Trust, W12 0HS, London, UK.
Michael BuchfelderDepartment of Neurosurgery, University of Duisburg-Essen, Essen, 45141, Germany.
Christine P BurrenDepartment of Paediatric Endocrinology, University Hospitals Bristol NHS Foundation Trust, Bristol, BS2 8HW, UK.
Alper GurlekDepartment of Endocrinology and Metabolism, Faculty of Medicine, Hacettepe University, Ankara, 06100, Turkey.
Pinaki DuttaDepartment of Endocrinology, PGIMER, Chandigarh, 160012, India.
Catherine S ChoongDepartment of Pediatric Endocrinology, Princess Margaret Hospital for Children, Subiaco, 6008, Australia.
Timothy CheethamNewcastle University c/o Department of Paediatric Endocrinology, Royal Victoria Infirmary, Newcastle-upon-Tyne, NE1 4LP, UK.
Giampaolo TrivellinSection on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH, Bethesda, MD, 20892, USA.
Constantine A StratakisSection on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH, Bethesda, MD, 20892, USA.
Maria-Beatriz LopesDepartment of Pathology, University of Virginia, Charlottesville, 22908, USA.
Ashley B GrossmanOxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, OX1 2JD, UK.
Jacqueline TrouillasDepartment of Pathology, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, 69500, France.
James R LupskiDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, 77030, USA.
Sian EllardInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, EX2 5DW, UK.
Julian R SampsonInstitute of Medical Genetics, Cardiff University, Cardiff, CF14 4XN, UK.
Federico RoncaroliInstitute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, M13 9PL, UK.
Márta KorbonitsCentre for Endocrinology, Barts and The London School of Medicine, London, EC1M 6BQ, UK. m.korbonits@qmul.ac.uk.
Queen Mary University of London · GBUniversity of Exeter · GBBaylor College of Medicine · USCardiff University · GBEunice Kennedy Shriver National Institute of Child Health and Human Development · USUniversity of Oxford · GBUniversity of Virginia · USBarts Health NHS Trust · GBCentro Medico Nacional Siglo XXI · MXHacettepe University · TRHospices Civils de Lyon · FRHospital de Especialidades · MXImperial College Healthcare NHS Trust · GBNewcastle University · GBOxford Centre for Diabetes, Endocrinology and Metabolism · GBPost Graduate Institute of Medical Education and Research · INPrincess Margaret Hospital for Children · AUUniversity Hospitals Bristol NHS Foundation Trust · GBUniversity of Duisburg-Essen · DEUniversity of Manchester · GB

Funding

Molecular Genetics of Endocrine Tumors and Related DisordersZIAHD008920 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI STRATAKIS, CONSTANTINE A. · 2012 to 2021
$25.8M
Baylor-Johns Hopkins Center for Mendelian GeneticsU54HG006542 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 2012 to 2015
$15.6M
Nonrecurrent rearrangements, genome architecture and neurodegenerative disease.R01NS058529 · NINDS · BAYLOR COLLEGE OF MEDICINE · PI LUPSKI, JAMES R. · 2009 to 2017
$5.0M
Medical Research Council MR/L022656/1Medical Research Council MR/M018539/1NHGRI NIH HHS U54 HG006542NINDS NIH HHS R01 NS058529Wellcome Trust
6 · The paper itself

Abstract

Non-syndromic pituitary gigantism can result from AIP mutations or the recently identified Xq26.3 microduplication causing X-linked acrogigantism (XLAG). Within Xq26.3, GPR101 is believed to be the causative gene, and the c.924G > C (p.E308D) variant in this orphan G protein-coupled receptor has been suggested to play a role in the pathogenesis of acromegaly.We studied 153 patients (58 females and 95 males) with pituitary gigantism. AIP mutation-negative cases were screened for GPR101 duplication through copy number variation droplet digital PCR and high-density aCGH. The genetic, clinical and histopathological features of XLAG patients were studied in detail. 395 peripheral blood and 193 pituitary tumor DNA samples from acromegaly patients were tested for GPR101 variants.We identified 12 patients (10 females and 2 males; 7.8 %) with XLAG. In one subject, the duplicated region only contained GPR101, but not the other three genes in found to be duplicated in the previously reported patients, defining a new smallest region of overlap of duplications. While females presented with germline mutations, the two male patients harbored the mutation in a mosaic state. Nine patients had pituitary adenomas, while three had hyperplasia. The comparison of the features of XLAG, AIP-positive and GPR101&AIP-negative patients revealed significant differences in sex distribution, age at onset, height, prolactin co-secretion and histological features. The pathological features of XLAG-related adenomas were remarkably similar. These tumors had a sinusoidal and lobular architecture. Sparsely and densely granulated somatotrophs were admixed with lactotrophs; follicle-like structures and calcifications were commonly observed. Patients with sporadic of familial acromegaly did not have an increased prevalence of the c.924G > C (p.E308D) GPR101 variant compared to public databases.In conclusion, XLAG can result from germline or somatic duplication of GPR101. Duplication of GPR101 alone is sufficient for the development of XLAG, implicating it as the causative gene within the Xq26.3 region. The pathological features of XLAG-associated pituitary adenomas are typical and, together with the clinical phenotype, should prompt genetic testing.

Indexed as

Gene DuplicationAcromegalyAdenomaAdolescentChildChild, PreschoolFemaleGerm-Line MutationGigantismHumansInfantIntracellular Signaling Peptides and ProteinsMalePituitary NeoplasmsReceptors, G-Protein-CoupledTreatment Outcomearyl hydrocarbon receptor-interacting proteinGPR101 protein, humanIntracellular Signaling Peptides and ProteinsReceptors, G-Protein-CoupledCNV mutationGigantismGPR101PituitaryXLAG

Identifiers

PMID27245663
PMCPMC4888203
OpenAlexW2417525412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.